Malignant pleural effusions (MPE) are commonly managed with either pleural catheter (PC) or talc pleurodesis (TP). The aim of this study was to compare survival in MPE patients treated with either PC or TP. A retrospective review of our cancer center database was performed. Patients with metastatic cancer and MPE were analyzed. Demographic and clinical data were tabulated and compared. A total of 238 patients with MPE treated by either PC or TP were included. Of these, 79 patients comprised the PC group and 159 the TP group. PC had a higher incidence of advanced disease (stage III or IV) at initial diagnosis compared with TP (70.9% vs 57.2%, P = 0.05). TP had a longer postprocedure length of stay compared with PC (7.1 vs 5.0 days, P = 0.02); however, overall length of stay was similar (9.7 vs 11.1 days, P = 0.34). Read-missions were significantly lower in TP (11.9% vs 22.8%, P = 0.04). Mean survival was higher in TP compared with PC (18.7 vs 4.1 months, P < 0.001). Patients with metastatic cancer and MPE treated with TP had significantly higher survival compared with PC. This is likely related to a greater disease burden in PC, as 70 per cent of patients in this group had stage III or IV disease on initial presentation.
Get full access to this article
View all access options for this article.
References
1.
FyshE.T., TremblayA., Feller-kopmanD.Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study.Chest2013; 144: 1597–602.
2.
HuntB.M., FarivarA.S., VallièresE.Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions.Ann Thorac Surg2012; 94: 1053–7.
3.
PuriV., PyrdeckT.L., CrabtreeT.D.Treatment of malignant pleural effusion: a cost-effectiveness analysis.Ann Thorac Surg2012; 94: 374–9.
4.
DaviesH.E., MishraE.K., KahanB.C.Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.JAMA2012; 307: 2383–9.
5.
PutnamJ.B., LightR.W., RodriguezR.M.A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions.Cancer1999; 86: 1992–9.
6.
SiorisT., SihvoE., SaloJ.Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.Eur J Surg Oncol2009; 35: 546–51.
7.
PutnamJ.B., WalshG.L., SwisherS.G.Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter.Ann Thorac Surg2000; 69: 369–75.
8.
KastelikJ.A.Management of malignant pleural effusion.Lung2013; 191: 165–75.
9.
YildirimH., MetintasM., AkG.Predictors of talc pleurodesis outcome in patients with malignant pleural effusions.Lung Cancer2008; 62: 139–44.
10.
FreemanR.K., AsciotiA.J., MahidharaR.S.A propensity-matched comparison of pleurodesis or tunneled pleural catheter in patients undergoing diagnostic thoracoscopy for malignancy.Ann Thorac Surg2013; 96(1): 259–63: discussion 263–4.
DemmyT.L., GuL., BurkhalterJ.E.Optimal management of malignant pleural effusions (results of CALGB 30102).J Natl Compr Canc Netw2012; 10: 975–82.
13.
SuzukiK., ServaisE.L., RizkN.P.Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters.J Thorac Oncol2011; 6: 762–7.
14.
PenzE.D., MishraE.K., DaviesH.E.Comparing cost of indwelling pleural catheter vs talc pleurodesis for malignant pleural effusion.Chest2014; 146: 991–1000.
15.
FyshE.T., WatererG.W., KendallP.A.Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion.Chest2012; 142: 394–400.
